News
ACC panel defines, advises on heart failure with ‘recovered’ EF
August 5, 2020
An American College of Cardiology expert panel has issued a definition of heart failure with recovered ejection fraction and recommendations for diagnosis and treatment.
News
Early palliative care fails to improve QOL in advanced heart failure
August 3, 2020
“My first reaction is disappointment. We had hoped to see the ENABLE program, which had been successful in cancer, translate to the heart failure setting.”
News
Heart damage even after COVID-19 ‘recovery’ evokes specter of later heart failure
July 31, 2020
Recovery from acute COVID-19 isn’t necessarily the end of it, clearly. Two reports aim to clarify how SARS-CoV-2 can directly invade the heart and indirectly cause persisting myocardial injury.
News
Hot-off-the-press insights on heart failure
July 20, 2020
This session provides literature updates for all types of heart failure patient scenarios.
News
Prior beta-blockers predict extra burden of heart failure in women with ACS
- Batya Swift Yasgur, MA, LSW
July 16, 2020
“Our provides robust evidence of an interaction between sex and beta-blocker therapy,” said Dr. Raffaele Bugiardini.
News
Dapagliflozin benefits low-EF heart failure regardless of diuretic dose: DAPA-HF
June 26, 2020
The trial that turned an SGLT2 inhibitor into a heart failure drug also has clues to mechanisms behind the observed benefits. Contrary to early speculation, diuresis may be off the list.
News
DAPA-HF: Dapagliflozin slows T2D onset in heart failure patients
June 16, 2020
In the landmark DAPA-HF trial that enrolled HFrEF patients without diabetes, treatment with dapagliflozin cut incident type 2 diabetes by a relative 32%.
News
FDA okays emergency use for Impella RP in COVID-19 right heart failure
June 2, 2020
The authorization allows use of the temporary heart pump in the treatment of right heart failure or decompensation, including pulmonary embolism, caused by COVID-19 complications.
News
FDA approves dapagliflozin for low-EF heart failure
May 7, 2020
The approval based on DAPA-HF makes dapagliflozin (Farxiga) the only drug in its class to be indicated for heart failure in the absence of diabetes.
News
Tools for preventing heart failure
February 13, 2020
SNOWMASS, COLO. – “There will be more than 1 million new cases of heart failure this year, and the vast majority of them could have been prevented.” – Gregg C. Fonarow, MD